MOVE — Corvex, Inc.

Movano Health Q3 2024 Earnings Call Summary

1. Key Financial Results and Metrics:

• Operating Loss: $7.4 million for Q3 2024, an improvement from a $9.1 million loss in Q3 2023.
• Cash Position: $11.3 million in cash and cash equivalents as of September 30, 2024.
• Cash Burn: Approximately $5.6 million for the quarter, including $1 million in one-time payments.
• Sales: 339 Evie Rings shipped during the third quarter following a successful back-in-stock launch on September 17.

2. Strategic Updates and Business Highlights:

• Product Development: Continued progress on the EvieMED Ring, with FDA 510(k) clearance anticipated soon. The EvieMED Ring will combine medical and wellness features.
• B2B Opportunities: Engaging with healthcare partners for pilot programs using EvieMED, including a major pharmaceutical company and a clinical research organization.
• Direct-to-Consumer (D2C) Strategy: Successful organic marketing efforts have led to a positive response from consumers, with plans for a paid marketing strategy during the holiday season.
• New Features: Launch of an Android app and a revised 60-day return policy aimed at enhancing customer experience.

3. Forward Guidance and Outlook:

• Sales Growth: Anticipation of increased sales volumes from both D2C and B2B channels, especially post-FDA clearance.
• Market Positioning: Movano aims to leverage its unique position as a medical device company in the growing smart ring market, which is expected to see approximately 1 million units sold in 2024.

4. Bad News, Challenges, or Points of Concern:

• Cash Management: While the company is focused on judicious capital spending, ongoing cash burn remains a concern as they navigate product launches and FDA processes.
• Market Competition: The entry of new competitors in the smart ring space poses a potential threat, although Movano believes its medical device background provides a competitive edge.
• Regulatory Risks: The FDA clearance process for EvieMED is complex and could face unforeseen delays or additional scrutiny.

5. Notable Q&A Insights:

• Blood Pressure Device Development: The company is optimistic about the accuracy of its cuffless blood pressure monitoring device, with ongoing trials expected to yield data soon.
• Android App Functionality: The Android app will match the iOS version in features, addressing significant consumer demand.
• Valuation Concerns: Management acknowledges the current undervaluation of the company relative to its assets and plans to enhance visibility to improve market perception.
• FDA Process Status: The company is in the final stages of the FDA review for EvieMED, having addressed prior questions primarily related to labeling and medical device aspects.

Overall, Movano Health is making significant strides in product development and market positioning, while carefully managing its financial resources amidst competitive pressures and regulatory challenges.